NICE approves new cholesterol lowering drug after NHS strikes deal with manufacturerBMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n2143 (Published 01 September 2021) Cite this as: BMJ 2021;374:n2143
- Jacqui Wise
- Kent, UK
A novel anti-cholesterol drug, to be given in primary care as a twice yearly injection, has been recommended for people with primary hypercholesterolaemia or mixed dyslipidaemia who have had a previous cardiovascular event.1
The National Institute for Health and Care Excellence (NICE) made the decision to recommend inclisiran after a “population level” commercial deal between NHS England and NHS Improvement and the drug’s manufacturer, Novartis. The manufacturer’s list price is £1987.36 (€2317; $2735) for a 284 mg dose pack, but the size of the NHS discount is confidential.
Meindert Boysen, NICE deputy chief executive and director of its Centre for Health Technology Evaluation, called inclisiran “a potential game changer in preventing thousands of people from dying prematurely …